Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In two Phase III randomized trials in MM, Ipi improved median overall survival (OS) [1, 2]. Here, we evaluate OS and characterize post-Ipi treatment patterns among long-term survivors from a single-institution cohort of patients (pts) treated with Ipi.
Through a search of institutional databases, we identified 766 pts with MM treated with Ipi between 1/1/2003 and 12/31/2013. As of 4/1/2014, 96 pts have survived ≥2 yrs, measured from first dose of Ipi. OS was calculated utilizing the Kaplan-Meier method. Disease control was defined as the duration from initiation of Tx until initiation of subsequent systemic Tx or death.
With a median follow-up of 17mo (range 0-9yr), the median OS for the entire cohort of 766 pts was 15mo, with a 2-yr OS of 41%. Of the 80 pts with OS ≥2 yrs post-Ipi for whom data are available, 75% (n = 60/80) remain alive and 30% (n = 24/80) remain progression-free following Ipi, with median Ipi disease control of 15mo (range: 3 to 107+mo). Among pts with progression (n = 56), 57% exhibited disseminated progression, 29% oligometastatic progression, and 15% CNS-only progression. The most frequent Tx at first progression was locoregional (n = 29), employed at a median of 11mo post-Ipi (range: 3 to 55mo) and associated with median 15+mos disease control (range 1 to 73+mo) (table 1). In pts requiring post-Ipi systemic Tx, long-term disease control was observed across multiple systemic Tx's (table 2).
Within this single-institution cohort, the median OS and 2-yr OS were greater than reported previously in Phase III trials [1, 2]. Potential reasons for this survival advantage include: referral bias, heterogeneous Ipi dosing/schedule, and access to subsequent trials (i.e. anti-PD-1/PD-L1, BRAF inhibitor). The majority of long-term survivors required subsequent Tx, however prolonged disease control was achieved with a range of Tx's. Pts who experience oligometastatic/CNS-only progression following Ipi may achieve prolonged disease control with locoregional Tx alone.